Daily Stock Analysis, CYTK, Cytokinetics Inc, priceseries

Cytokinetics Inc. Daily Stock Analysis
Stock Information
Open
9.18
Close
9.55
High
9.75
Low
9.14
Previous Close
9.25
Daily Price Gain
0.30
YTD High
14.94
YTD High Date
Sep 6, 2019
YTD Low
5.75
YTD Low Date
Mar 7, 2019
YTD Price Change
2.73
YTD Gain
40.03%
52 Week High
14.94
52 Week High Date
Sep 6, 2019
52 Week Low
5.75
52 Week Low Date
Mar 7, 2019
52 Week Price Change
2.19
52 Week Gain
29.76%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 1. 2017
11.05
Mar 17. 2017
12.47
12 Trading Days
12.82%
Link
LONG
Apr 18. 2017
12.95
May 5. 2017
15.47
13 Trading Days
19.49%
Link
LONG
Jul 11. 2017
13.10
Jul 27. 2017
14.02
12 Trading Days
7.00%
Link
LONG
Aug 24. 2017
12.75
Sep 12. 2017
14.05
12 Trading Days
10.19%
Link
LONG
Apr 26. 2018
7.70
May 21. 2018
8.83
17 Trading Days
14.69%
Link
LONG
Sep 21. 2018
8.50
Oct 1. 2018
9.08
6 Trading Days
6.79%
Link
LONG
Nov 19. 2018
6.85
Dec 4. 2018
7.60
10 Trading Days
11.01%
Link
LONG
Mar 12. 2019
6.77
Mar 27. 2019
8.43
11 Trading Days
24.58%
Link
LONG
Apr 22. 2019
8.47
Apr 30. 2019
8.93
6 Trading Days
5.43%
Link
Company Information
Stock Symbol
CYTK
Exchange
NasdaqGS
Company URL
http://www.cytokinetics.com
Company Phone
(650) 624-3000
CEO
Robert I. Blum
Headquarters
California
Business Address
280 EAST GRAND AVENUE, ., SOUTH SAN FRANCISCO, CA 94080
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001061983
About

Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.

Description

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its lead drug candidate is Tirasemtiv, a fast skeletal troponin activator, which is in Phase III clinical trial in patients with amyotrophic lateral sclerosis. Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency. The company is preparing for the commercialization of Tirasemtiv in North America and Europe, as well as has granted an option to Astellas Pharma Inc. for development and commercialization in other countries. The company has strategic alliances with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator that is in two ongoing Phase II clinical trials enrolling patients with spinal muscular atrophy and chronic obstructive pulmonary disease, as well as other indications associated with muscle weakness; and with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, which is in Phase III clinical trial in patients with heart failure. Amgen Inc. holds an exclusive worldwide license to develop and commercialize omecamtiv mecarbil with a sublicense held by Servier for commercialization in Europe and other countries; and Astellas Pharma Inc. holds an exclusive worldwide license to develop and commercialize omecamtiv mecarbil and related compounds. The company was founded in 1997 and is headquartered in South San Francisco, California.